Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies
Francesco Passamonti, Alessandra Romano, Marco Salvini, et al.
British Journal of Haematology (2021) Vol. 195, Iss. 3, pp. 371-377
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

COVID-19 in patients with hematologic malignancy
Petra Langerbeins, Michael Hallek
Blood (2022) Vol. 140, Iss. 3, pp. 236-252
Open Access | Times Cited: 110
T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies
Vincenzo Marasco, Cristiana Carniti, Anna Guidetti, et al.
British Journal of Haematology (2021) Vol. 196, Iss. 3, pp. 548-558
Open Access | Times Cited: 90
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
Nico Gagelmann, Francesco Passamonti, Christine Wolschke, et al.
Haematologica (2021) Vol. 107, Iss. 8, pp. 1840-1849
Open Access | Times Cited: 67
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
Christian Buske, Martin Dreyling, Alberto Álvarez‐Larrán, et al.
ESMO Open (2022) Vol. 7, Iss. 2, pp. 100403-100403
Open Access | Times Cited: 53
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1175-1185
Open Access | Times Cited: 33
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
Carlo Visco, Luigi Marcheselli, Roberto Mina, et al.
Blood Advances (2021) Vol. 6, Iss. 1, pp. 327-338
Open Access | Times Cited: 45
Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study
Paolo Corradini, Chiara Agrati, Giovanni Apolone, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e426-e438
Open Access | Times Cited: 31
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Heinz Ludwig, Pieter Sonneveld, Thierry Façon, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 12, pp. e934-e946
Open Access | Times Cited: 33
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
Giuseppe A. Palumbo, Daniela Cambria, Enrico La Spina, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 14
Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population
Adeel A. Butt, Yan Peng, Obaid S. Shaikh, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e849-e856
Open Access | Times Cited: 29
Efficacy and safety of tixagevimab‐cilgavimab versus SARS‐CoV‐2 breakthrough infection in the hematological conditions
Andrea Duminuco, Antonella Nardo, Alessandra Orofino, et al.
Cancer (2023) Vol. 130, Iss. 1, pp. 41-50
Closed Access | Times Cited: 12
COVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?
André Luiz Melo Camelo, Hans Rolando Zamora-Obando, Isabela Rocha, et al.
Metabolites (2024) Vol. 14, Iss. 4, pp. 195-195
Open Access | Times Cited: 4
The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose
Fabio Fiorino, Anna Sicuranza, Annalisa Ciabattini, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1480-1480
Open Access | Times Cited: 25
Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations
Francesco Passamonti, Emanuele Nicastri, Alice Di Rocco, et al.
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 3-15
Open Access | Times Cited: 19
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia
Annalisa Chiarenza, Gaia Vertillo Aluisio, Nunziatina Laura Parrinello, et al.
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
ORCHESTRA Delphi Consensus: diagnostic and therapeutic management of SARS-CoV-2 infection in haematological patients
Lorenzo Maria Canziani, Anna Maria Azzini, Jon Salmanton‐García, et al.
Clinical Microbiology and Infection (2025)
Closed Access
Serological response following BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccination in haematopoietic stem cell transplantation patients
Immacolata Attolico, Francesco Tarantini, Paola Carluccio, et al.
British Journal of Haematology (2021) Vol. 196, Iss. 4, pp. 928-931
Open Access | Times Cited: 23
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
María Stefania Infante, Jon Salmanton‐García, Ana Fernández‐Cruz, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 16
COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response
Ivan Gur, Amir Giladi, Yonathan Nachum Isenberg, et al.
Acta Haematologica (2022) Vol. 145, Iss. 3, pp. 297-309
Open Access | Times Cited: 15
Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitant hematological malignancies: An Italian retrospective study
Francesco Lanza, Federica Monaco, Fabio Ciceri, et al.
Hematological Oncology (2022) Vol. 40, Iss. 5, pp. 857-863
Open Access | Times Cited: 13
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies
Luis‐Esteban Tamariz‐Amador, Anna Martina Battaglia, Catarina Maia, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 12
Open Access | Times Cited: 18
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort
Michele Merli, Isacco Ferrarini, Francesco Merli, et al.
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 128-138
Open Access | Times Cited: 12
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
Francesco Angotzi, Marco Petrella, Tamara Berno, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak
Milena Kohn, Tamim Alsuliman, Sylvain Lamure, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2022) Vol. 63, Iss. 11, pp. 2686-2690
Open Access | Times Cited: 11
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation
Marco Salvini, Fabrizio Maggi, Camilla Damonte, et al.
Bone Marrow Transplantation (2021) Vol. 57, Iss. 1, pp. 137-139
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top